Thiel-backed Lindus sells CRO arm in pivot to hunt for drug assets
A Peter Thiel-backed transatlantic startup that once branded itself as an “anti-CRO” is pivoting from a clinical trials operator to a drug developer. Lindus Therapeutics is betting that its experience over ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.